Anika expects updated 2025 revenue ranges by segment as follows: Commercial Channel, unchanged, of $47 to $49.5 million, up 12% – 18% year-over-year; OEM Channel of $62 to $65 million, down 16% – 20% year-over-year, as a result of lower forecasts on end user pricing from J&J MedTech as compared to our prior range of down 12% – 18% year-over-year. The Company is updating its guidance for Adjusted EBITDA to -3% to 3%, previously 8% to 10%, as a result of lower end-user pricing for Monovisc and Orthovisc, lower first half manufacturing yields, the costs for the Cingal bioequivalence study, and the known impacts associated with recently announced tariffs.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK:
- Is ANIK a Buy, Before Earnings?
- Microsoft, PayPal downgraded: Wall Street’s top analyst calls
- Anika Therapeutics initiated with a Buy at B. Riley
- Anika Therapeutics Announces COO Departure and Role Elimination
- Anika Therapeutics Faces Financial Strain Amid Geopolitical Tensions and Supply Chain Disruptions
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue